Teva Pharmaceutical Industries Ltd. today announced the launch of generic Pataday1 (olopatadine hydrochloride ophthalmic solution) 0.2%, in the U.S.
Olopatadine hydrochloride ophthalmic solution 0.2% is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.
With nearly 600 generic medicines available, Teva has the largest portfolio of FDA-approved generic products on the market. Currently, one in six generic prescriptions dispensed in the U.S. is filled with a Teva product.
“Olopatadine hydrochloride ophthalmic solution 0.2% is an important treatment for our patients and a key addition to our generics product portfolio,” said Dipankar Bhattacharjee, Teva’s president and CEO, Global Generic Medicines. “This launch marks another successful first-to-file product for Teva, bringing the only generic version of this product on the market.”
Pataday had annual sales of approximately $303 million in the U.S., according to IMS data as of March 2017.
1 Pataday® is a registered trademark of Alcon Laboratories, Inc., a Novartis company.
(Source: Business Wire)